ArriVent BioPharma Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 14, 2024
Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases
Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025
Read more at globenewswire.com
